Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...